Title Design, synthesis and biological characterization of novel inhibitors of CD38
Authors Dong, Min
Si, Yuan-Qi
Sun, Shuang-Yong
Pu, Xiao-Ping
Yang, Zhen-Jun
Zhang, Liang-Ren
Zhang, Li-He
Leung, Fung Ping
Lam, Connie Mo Ching.
Kwong, Anna Ka Yee
Yue, Jianbo
Zhou, Yeyun
Kriksunov, Irina A.
Hao, Quan
Lee, Hon Cheung
Affiliation Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China.
Univ Hong Kong, Dept Physiol, Hong Kong, Hong Kong, Peoples R China.
Cornell Univ, Cornell High Energy Synchrotron Source, MacCHESS, Ithaca, NY 14853 USA.
Keywords CYCLIC ADP-RIBOSE
ADENINE-DINUCLEOTIDE
CRYSTAL-STRUCTURE
BASIC SCIENCE
NAADP
DIFFERENTIATION
IDENTIFICATION
GLYCOHYDROLASE
STIMULATION
CONTRACTION
Issue Date 2011
Publisher organic biomolecular chemistry
Citation ORGANIC & BIOMOLECULAR CHEMISTRY.2011,9,(9),3246-3257.
Abstract Human CD38 is a novel multi-functional protein that acts not only as an antigen for B-lymphocyte activation, but also as an enzyme catalyzing the synthesis of a Ca(2+) messenger molecule, cyclic ADP-ribose, from NAD(+). It is well established that this novel Ca(2+) signaling enzyme is responsible for regulating a wide range of physiological functions. Based on the crystal structure of the CD38/NAD(+) complex, we synthesized a series of simplified N-substituted nicotinamide derivatives (Compound 1-14). A number of these compounds exhibited moderate inhibition of the NAD(+) utilizing activity of CD38, with Compound 4 showing the highest potency. The crystal structure of CD38/Compound 4 complex and computer simulation of Compound 7 docking to CD38 show a significant role of the nicotinamide moiety and the distal aromatic group of the compounds for substrate recognition by the active site of CD38. Biologically, we showed that both Compounds 4 and 7 effectively relaxed the agonist-induced contraction of muscle preparations from rats and guinea pigs. This study is a rational design of inhibitors for CD38 that exhibit important physiological effects, and can serve as a model for future drug development.
URI http://hdl.handle.net/20.500.11897/156714
ISSN 1477-0520
DOI 10.1039/c0ob00768d
Indexed SCI(E)
EI
PubMed
Appears in Collections: 药学院
天然药物与仿生药物国家重点实验室

Web of Science®


33

Checked on Last Week

Scopus®



Checked on Current Time

百度学术™


0

Checked on Current Time

Google Scholar™





License: See PKU IR operational policies.